Here's Why Harmony Biosciences Is an Unconventional Cannabis Investment

Harmony Biosciences (HRMY) reported robust Q1 2025 sales of $185 million, driven by its flagship narcolepsy drug Wakix, and maintains a strong cash position of $610 million. A significant near-term catalyst is the anticipated top-line Phase III data for ZYN-002, an investigational synthetic CBD gel for Fragile X Syndrome, expected by September, which could establish a first-in-class treatment. The company is also advancing next-generation Wakix formulations and epilepsy assets, diversifying its pipeline to mitigate future exclusivity risks for Wakix and expand its neurobehavioral footprint, while navigating competition from firms like Jazz Pharmaceuticals.

Analysis

Harmony Biosciences (HRMY) presents a compelling case of a profitable commercial-stage company leveraging current success to fund a high-stakes pipeline transition. The company's sole revenue driver, the narcolepsy drug Wakix, continues to exhibit strong commercial momentum, with sales growing 20% year-over-year to $185 million in the first quarter of 2025 and a full-year guidance suggesting approximately 18% growth. This performance supports a robust $610 million cash position, which is critical for funding its diversification strategy ahead of Wakix's expected loss of exclusivity by the end of the decade. The most significant near-term inflection point for the company is the top-line data from the Phase III RECONNECT study for its synthetic CBD gel, ZYN-002, anticipated by the end of September. A positive outcome would not only provide a potential first-in-class therapy for Fragile X Syndrome but also validate the 2023 acquisition of Zynerba Pharmaceuticals and open a new therapeutic avenue in neurobehavioral disorders. However, despite this pipeline potential and solid fundamentals, the stock has underperformed its industry with a 7% year-to-date decline, likely reflecting investor caution following a recent regulatory setback for a Wakix label expansion and the significant competitive overlap with Jazz Pharmaceuticals in both sleep disorders and epilepsy.

Key Decisions for Investors

• Closely monitor the top-line data from the ZYN-002 Phase III study due by September's end, as this is the primary near-term catalyst with the potential to significantly de-risk the pipeline and re-rate the stock.
• Evaluate the competitive landscape, particularly the performance of Wakix against Jazz Pharmaceuticals' therapies, as this remains the core determinant of the company's near-term cash flow and ability to fund its pipeline.
• Consider the current valuation in light of the stock's recent underperformance, but weigh this against the high-stakes binary risk of the upcoming ZYN-002 data readout and the company's long-term need to successfully diversify beyond Wakix.